Advancing pipeline with purpose
Interim Report Q3 2026
“These advances reflect the growing maturity of our pipeline, and across three differentiated programs, our focus is on measurable clinical, regulatory and preclinical milestones.”
CEO
Financial Calendar
View allPress releases
View all20 Nov 2026
Cereno Scientific invites shareholders and investors to a digital investor meeting and Q&A
18 Nov 2026
Cereno Scientific Achieves Key Clinical Milestone as First Patient Is Dosed in Global Phase IIb EPIMODE Trial of CS1 in PAH
17 Nov 2026
Cereno Scientific announces resignation of Chairperson of the Board at his own request
Featured highlights
View allAnalyst report
12 Jan 2026
Cereno Scientific - Entering a value inflection phase
An outlook by Jyoti Prakesh, Edison.
Analysts
New analyst coverage
Leading global investment bank Stifel has initiated equity research coverage of the company in March 2026. The initiation reflects growing external interest in the company.
Presentation
Capital Markets Day 2026
A recording of the company's CMD held on February 5, 2026.
Governance
Corporate governance
Cereno Scientific is committed to high standards of corporate governance, transparency, and accountability. Our governance framework supports responsible decision-making, long-term value creation, and trust among shareholders and stakeholders.
We adhere to applicable regulations and best practices for companies listed on Nasdaq First North Growth Market.
Deeper insights
Stories
Insights and explainers to support understanding of the field, our activities and why innovation in medicine matters.
Explore more
Contact
Investor questions
Tove Bergenholt, Head of IR & Communications
Email: [email protected]
Phone: +46(0)732-366 246